Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AA39959 for Depression in Bipolar Disorder
NCT00771134Phase 2Terminated
- Sponsor
- Lundbeck
- Start
- Dec 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lu AA39959 in bipolar disorder (BD) (3 arms), sponsored by Lundbeck. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Dec 2008; status: terminated.
02
Drugs
Lu AA39959
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00771134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771134.